Carrier Erica J, Kearn Christopher S, Barkmeier Andrew J, Breese Nicole M, Yang Wenqi, Nithipatikom Kasem, Pfister Sandra L, Campbell William B, Hillard Cecilia J
Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226-0509, USA.
Mol Pharmacol. 2004 Apr;65(4):999-1007. doi: 10.1124/mol.65.4.999.
Microglia, as phagocytes and antigen-presenting cells in the central nervous system, are activated in such disease processes as stroke and multiple sclerosis. Because peripheral macrophages are capable of producing endocannabinoids, we have examined endocannabinoid production in a macrophage-colony stimulating factor (M-CSF)-dependent rat microglial cell line (RTMGL1) using reversed phase high-pressure liquid chromatography and liquid chromatography-mass spectroscopy. We determined that cultured microglial cells produce the endocannabinoid 2-arachidonylglycerol (2-AG) as well as anandamide in smaller quantities. When 2-AG, but not anandamide, is added exogenously, RTMGL1 microglia increase their proliferation. This increased proliferation is blocked by an antagonist of the CB(2) receptor N-[(1S)endo-1,3,3-trimethyl bicyclo heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide (SR144528) and mimicked by the CB(2) receptor-specific agonist 1,1-dimethylbutyl-1-deoxy-Delta(9)-tetrahydrocannabinol (JWH133). Accompanying the increase in proliferation seen with 2-AG is an increase in active ERK1 that is also blocked with SR144528. The RTMGL1 microglial cells, which exist in a primed state, express the CB(1) and CB(2) receptors as demonstrated by reverse transcription-polymerase chain reaction and immunostaining. The CB(2) receptor in untreated cells is expressed both at the cell surface and internally, and exposure of the cells to 2-AG significantly increases receptor internalization. These data suggest that 2-AG activation of CB(2) receptors may contribute to the proliferative response of microglial cells, as occurs in neurodegenerative disorders.
小胶质细胞作为中枢神经系统中的吞噬细胞和抗原呈递细胞,在中风和多发性硬化症等疾病过程中被激活。由于外周巨噬细胞能够产生内源性大麻素,我们使用反相高压液相色谱法和液相色谱-质谱法,检测了巨噬细胞集落刺激因子(M-CSF)依赖性大鼠小胶质细胞系(RTMGL1)中内源性大麻素的产生。我们确定,培养的小胶质细胞会产生内源性大麻素2-花生四烯酸甘油酯(2-AG),以及少量的花生四烯酸乙醇胺。当外源性添加2-AG而非花生四烯酸乙醇胺时,RTMGL1小胶质细胞的增殖会增加。CB(2)受体拮抗剂N-[(1S)endo-1,3,3-三甲基双环庚烷-2-基]-5-(4-氯-3-甲基苯基)-1-(4-甲基苄基)-吡唑-3-甲酰胺(SR144528)可阻断这种增殖增加,而CB(2)受体特异性激动剂1,1-二甲基丁基-1-脱氧-Δ(9)-四氢大麻酚(JWH133)可模拟这种增加。伴随2-AG导致的增殖增加,活性ERK1也会增加,而SR144528同样可阻断这种增加。通过逆转录-聚合酶链反应和免疫染色证明,处于预激活状态的RTMGL1小胶质细胞表达CB(1)和CB(2)受体。未处理细胞中的CB(2)受体在细胞表面和内部均有表达,细胞暴露于2-AG会显著增加受体内化。这些数据表明,CB(2)受体的2-AG激活可能有助于小胶质细胞的增殖反应(如在神经退行性疾病中发生的那样)。